← Back to patent-cliff list
琥珀酸舒马普坦
Tier C — Watch / tradeSumatriptan Succinate
葛兰素史克
Originator
1991
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：5-HT
Brand：Sumavel DosePro、Imigrane、Imigran、Imigran/Imitrex、Alsuma、Imitrex、Onzetra Xsail、Suminat
Indications (approved)：丛集性头痛、偏头痛
Regional status
US
批准上市
1992-12-28
EU
终止
China
批准上市
2003-01-30
Japan
批准上市
2000-04-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sumatriptan Succinate?
Approved indications include: 丛集性头痛, 偏头痛.
When does the Sumatriptan Succinate patent expire?
No public expiry year is available for Sumatriptan Succinate yet; this page updates once verified.
How do I get a quote for Sumatriptan Succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25